, (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, is pleased to announce today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback